Tuesday, 28 April 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 28 April 2026
News

PBAC greenlights new drugs

Posted 28 April 2026 AM

Out of 26 new PBS listing submissions considered by the PBAC in March, a massive 23 submissions were recommended while one was deferred and only two were knocked back.

Swedish Orphan Biovitrum’s diffuse large B-cell lymphoma treatment Zynlonta and Amgen’s extensive-stage small cell lung cancer treatment Imdelltra were both knocked back while BioMarin’s Palynziq for phenylketonuria was deferred. All three drugs are yet to appear on the scheme.

To see the whole article, please login

Popular

MD's message to Dept workers
Long-timers jumping companies
Aussie pharma naughty or nice?
Real World Evidence feud goes legal
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home